GlassScriptPhysician profile
Francis Le
NPI 1134236508
$7,298.30
in general payments reported to CMS, 2019-2025
31 companies · $683 in 2025
The $683 reported for 2025 was less than what a typical Clinical Cardiac Electrophysiology provider received nationally (typical 2025 total: $2,477).
See the full distribution for Clinical Cardiac Electrophysiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $660 · 2020: $382 · 2021: $2,526 · 2022: $1,242 · 2023: $1,102 · 2024: $703 · 2025: $683.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,399 · Education: $88.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,398.97 |
| Education | $88.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,036.88 | 2020-2025 | Jot Dx, Allure Quadra, Fortify Assura |
| Medtronic, INC. | $1,781.79 | 2021-2023 | Micra |
| Boston Scientific Corporation | $1,528.66 | 2019-2025 | Accolade Sr |
| Actelion Pharmaceuticals US, INC. | $322.40 | 2022-2025 | Opsumit, Uptravi |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $200.37 | 2022-2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $184.32 | 2019-2024 | |
| Abiomed | $148.17 | 2025 | |
| Merck Sharp & Dohme LLC | $130.94 | 2023-2025 | Verquvo, Winrevair |
| Astrazeneca Pharmaceuticals LP | $128.67 | 2020-2024 | Farxiga |
| Shockwave Medical, INC | $102.43 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $91.64 | 2021-2025 | |
| Medtronic Vascular, INC. | $91.59 | 2019-2020 | |
| Amarin Pharma, INC. | $65.30 | 2019 | |
| Kestra Medical Technology Services, INC. | $63.25 | 2025 | Assure Wcd |
| Aerin Medical INC. | $43.13 | 2019 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $39.28 | 2022-2023 | Injectafer |
| Regeneron Healthcare Solutions, INC. | $34.96 | 2025 | Evkeeza |
| Amgen INC. | $34.49 | 2020-2025 | Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.78 | 2023 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $26.47 | 2025 | Eliquis |
| Sanofi-Aventis U.S. LLC | $25.97 | 2023 | |
| Scpharmaceuticals INC. | $25.95 | 2024 | |
| Impulse Dynamics (USA) INC. | $22.06 | 2023 | Optimizer |
| Kiniksa Pharmaceuticals International, Plc | $21.79 | 2024 | Arcalyst |
| Lexicon Pharmaceuticals, INC. | $19.44 | 2023 | Inpefa |
| Chiesi USA, INC. | $18.98 | 2025 | Kengreal |
| Janssen Pharmaceuticals, INC | $17.88 | 2023 | Xarelto |
| Pfizer INC. | $16.85 | 2025 | |
| Teleflex LLC | $15.66 | 2025 | Twin-Pass |
| Philips North America LLC | $13.61 | 2022 | |
| Ethicon US, LLC | $12.59 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Francis Le listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.